04-10-2021 AML-FLT 3+ and NPM mutated AML, incorporating the molecular aspects

See more from BLOODSA

Haem Deep Dive

07-10-2024 How Do I Treat ClLL in 2024

Timestamps:

October 7, 2024

BMT Classroom

02-10-2024 BMT: Classroom

This content is only available to members.

October 2, 2024

Haem Deep Dive

30-09-2024 Essential Insights Gained on Emicizumab: Navigating Surgery and Comorbidities

Timestamps:

September 30, 2024

All resources showcased on this website are provided by BLOODSA in collaboration with our partners. It may be used and shared for non-commercial purposes only with proper acknowledgement to BLOODSA and respective authors (if applicable) and the information must remain accessible in the public domain.

We are in Strategic Partnership with:

Room E4-58, E5 Haematology Clinic E-floor, New Main Building, Groote Schuur Hospital, Observatory, CAPE TOWN 7935

+27 (0) 21 404 3070 | admin@bloodsa.org.za

BLOODSA Foundation NPC is registered in South Africa with Company Reg. No: 2021/990954/08, Non-Profit Organisation Reg. No: 268-421 NPO and Public Benefit Organisation Ref. No: 930076265

About
Services
Contact
Consortium Agreement
Code of Coduct
Cookie Policy
Privacy Policy
Popia Statement

About
Services
Contact
Consortium Agreement
Code of Coduct
Cookie Policy
Privacy Policy
Popia Statement

Scroll to Top

04-10-2021 AML-FLT 3+ and NPM mutated AML, incorporating the molecular aspects

See more from BLOODSA

07-10-2024 How Do I Treat ClLL in 2024

02-10-2024 BMT: Classroom

30-09-2024 Essential Insights Gained on Emicizumab: Navigating Surgery and Comorbidities

BACK TO RESOURCES